References
- Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol 2014;133(2):318-23
- Bielory L, Skoner DP, Blaiss MS, et al. Ocular and nasal allergy symptom burden in America: the allergies, immunotherapy and rhinoconjunctivitis (airs) survey. Allergy Asthma Proc 2014;35(3):211-18
- Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009;124(1):150-6
- Brehler R, Klimek L, Pfaar O, et al. Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. Allergy Asthma Proc 2010;31(3):e31-8
- Pfaar O, Biedermann T, Klimek L, et al. Depigmented-polymerized mixed grass/birth pollen extract immunotherapy is effective in polysensitized patients. Allergy 2013;68(10):1306-13
- Henmar H, Lung G, Lund L, et al. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol 2008;153(3):316-23
- Jutel M, Akdis CA. Novel immunotherapy vaccine development. Curr Opin Allergy Clin Immunol 2014;14(6):557-63
- Jongejan L, van Ree R. Modified allergens and their potential to treat allergic disease. Curr Allergy Asthma Report 2014;14(12):478-87
- Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. PNAS 2008;105(46):17908-12
- Senti G, von Moos S, Tay F, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015;70(6):707-10
- Rotirooti G, Shamji M, Durham SR, Till SJ. Repeated low-dose intradermal allergen injections suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol 2012;130(4):918-24
- Witten M, Malling HJ, Blom L, et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 2013;132(5):1248-52
- Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125(2):383-9
- Niespodziana K, Focke-Tejkl M, Linhart B, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011;127(6):1562-70
- Couroux P, Patel D, Armstrong K, et al. Fed d -1-derived synthetic peptide immune-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015;45(5):974-81
- DuBuskie LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32(3):239-47
- Petel P, Holdich T, Fischer von Weikerstah-Drachenberg KJ, Humber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. JACI 2014;133:121-9
- Beeh KM, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. JACI 2013;131(3):866-74
- Cytos Biotechnology AG website, 14 April 2014 Press Release